Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics (CSE:RVV) among 17 companies listed in first psychedelics ETF

Simon Druker January 22, 2021

IIROC Trade Resumption - RVV

Canada NewsWire January 21, 2021

Revive Therapeutics Announces Upsize to Previously Announced Bought Deal Offering

Canada NewsWire January 21, 2021

IIROC Trading Halt - RVV

Canada NewsWire January 21, 2021

Revive Therapeutics Announces $10 Million Bought Deal Offering of Units

Canada NewsWire January 20, 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

GlobeNewswire January 14, 2021

Psilocybin is Being Studied to Help Treat Autism Spectrum Disorder

Livemoney January 13, 2021

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

GlobeNewswire December 31, 2020

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

GlobeNewswire December 23, 2020

PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics

GlobeNewswire December 21, 2020

Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program

GlobeNewswire December 21, 2020

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

GlobeNewswire December 2, 2020

Psilocybin Medical Play Advances Business, Ready for Next Stage

Stockhouse Editorial November 25, 2020

PharmaTher Provides Update on its Psychedelic Pharmaceuticals Programs

GlobeNewswire November 24, 2020

PharmaTher & Revive Therapeutics Team-Up to Investigate Psychedelic Cancer Treatment Therapies

Stockhouse Editorial November 18, 2020

This Could be Game-Changing News for Psilocybin's Treatment of Mental Health

Livemoney November 18, 2020

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

GlobeNewswire November 18, 2020

PharmaTher Enters Into Research Collaboration with Revive Therapeutics for Psilocybin and panaceAI(TM) Psychedelic Discovery AI Platform

GlobeNewswire November 18, 2020

Aside from Depression, Psilocybin May Be a Natural Appetite Suppressant

Livemoney November 12, 2020

Psilocybin - One of the Biggest Winners of the 2020 U.S. Election

Livemoney November 11, 2020